Primary Hyperparathyroidism
A condition where a benign tumor on a parathyroid gland produces too much parathyroid hormone, pulling calcium out of bones and into the blood.
Emergency Management: Severe hypercalcemia (Calcium > 14 mg/dL) presenting with altered mental status requires aggressive IV hydration with Normal Saline (200-300 mL/hr) followed by IV Calcitonin (4 IU/kg) and IV Bisphosphonates (e.g., Zoledronic acid 4 mg).
Primary hyperparathyroidism is a common endocrine disorder characterized by the autonomous, excessive secretion of parathyroid hormone (PTH) from one or more of the parathyroid glands, resulting in hypercalcemia.
Detailed Overview
It is the most common cause of hypercalcemia in the outpatient setting. PTH tightly regulates calcium homeostasis by acting on the bones, kidneys, and intestines. In PHPT, the normal negative feedback loop is lost. The classic phenotype of 'bones, stones, abdominal groans, and psychic moans' is rarely seen today; instead, >80% of patients are completely asymptomatic at diagnosis, discovered incidentally on routine blood panels. Despite being asymptomatic, chronic mild hypercalcemia can lead to silent nephrolithiasis and decreased cortical bone density (osteoporosis).
Epidemiology & Demographics
Prevalence is 1-4 per 1,000. Incidence peaks in the sixth decade of life. Females are affected 3 times more often than males, commonly occurring post-menopause.
Etiological Mechanism
Solitary parathyroid adenoma is responsible for 80-85% of cases. Multiple gland hyperplasia accounts for 10-15%. Parathyroid carcinoma is extremely rare (<1%). Most are sporadic, but ~5% are associated with MEN1 or MEN2A syndromes.
Primary Causes
Clonal proliferation of parathyroid chief cells forming an adenoma, often driven by somatic mutations in the PRAD1 (cyclin D1) or MEN1 genes.
The parathyroid glands possess calcium-sensing receptors (CaSR). Normally, high serum calcium suppresses PTH release. In PHPT, an adenoma or hyperplastic glands have a raised 'set-point' or decreased sensitivity to calcium, continuously secreting PTH. Excess PTH acts directly on the osteoblasts, upregulating RANKL, which strongly activates osteoclasts, leading to bone resorption and calcium release. In the kidney, PTH increases calcium reabsorption in the distal tubule and decreases phosphate reabsorption, while also stimulating 1-alpha-hydroxylase to convert Vitamin D to its active form (calcitriol). Increased calcitriol enhances intestinal calcium absorption. The net result is hypercalcemia, hypophosphatemia, and hypercalciuria (because the filtered load of calcium eventually exceeds the tubular reabsorptive capacity, risking stone formation).
Diagnostic Criteria & Guidelines
Simultaneous finding of elevated total or ionized serum calcium WITH an elevated or inappropriately high-normal intact PTH level. Requires 24-hour urine calcium collection to rule out Familial Hypocalciuric Hypercalcemia (FHH).
For Symptomatic patients or Asymptomatic patients meeting surgical criteria (Age <50, Calcium >1.0 mg/dL above normal, T-score < -2.5, Creatinine clearance <60 mL/min, or urine Ca >400 mg/d): Minimally invasive parathyroidectomy. Surgery is the only definitive cure.
Second-Line & Adjunctive Therapy
For patients who are poor surgical candidates or refuse surgery: Cinacalcet (calcimimetic) 30 mg PO daily (lowers serum calcium but does not improve bone density). Bisphosphonates (e.g., Alendronate 70mg weekly) to improve bone density without significantly lowering serum calcium.
Surgical & Procedural Management
Minimally invasive targeted parathyroidectomy guided by pre-operative localization (Sestamibi/US) and confirmed with Intraoperative PTH monitoring (IOPTH). PTH has a half-life of 4 minutes; a >50% drop in IOPTH 10 minutes post-excision confirms cure.
Patient Counseling & Advice
Reassure patients that parathyroid tumors are almost never cancerous (>99% benign). Emphasize the importance of hydration. Clarify that restricting dairy products will not fix the problem and may worsen bone loss.
Follow-Up & Monitoring Schedule
For patients managed non-surgically: Serum calcium and creatinine every 6 months, and DEXA scan every 1-2 years. Post-operatively: monitor for transient hypocalcemia (perioral numbness, tingling) in the first 24-48 hours.
Preventive Strategies
No primary prevention available. Secondary prevention focuses on preventing kidney stones (hydration) and bone loss (vitamin D supplementation if deficient, as low vitamin D exacerbates PTH secretion).
Surgical cure rate is >95% when performed by an experienced endocrine surgeon. Post-operatively, bone mineral density improves significantly over 1-2 years, and kidney stone risk drops rapidly.